ABSTRACT Anti-human immunodeficiency virus type 1 (HIV-1) nonneutralizing antibodies (nnAbs) capable of antibody-dependent cellular cytotoxicity (ADCC) have been identified as a protective immune correlate in the RV144 vaccine efficacy trial. Broadly neutralizing antibodies (bNAbs) also mediate ADCC in cell culture and rely on their Fc region for optimal efficacy in animal models. Here, we selected 9 monoclonal nnAbs and 5 potent bNAbs targeting various epitopes and conformations of the gp120/41 complex and analyzed the potency of the two types of antibodies to bind and eliminate HIV-1-infected cells in culture. Regardless of their neutralizing activity, most of the selected antibodies recognized and killed cells infected with two laboratory-adapted HIV-1 strains. Some nnAbs also bound bystander cells that may have captured viral proteins. However, in contrast to the bNAbs, the nnAbs bound poorly to reactivated infected cells from 8 HIV-positive individuals and did not mediate effective ADCC against these cells. The nnAbs also inefficiently recognize cells infected with 8 different transmitted-founder (T/F) isolates. The addition of a synthetic CD4 mimetic enhanced the binding and killing efficacy of some of the nnAbs in an epitope-dependent manner without reaching the levels achieved by the most potent bNAbs. Overall, our data reveal important qualitative and quantitative differences between nnAbs and bNAbs in their ADCC capacity and strongly suggest that the breadth of recognition of HIV-1 by nnAbs is narrow.
B
roadly neutralizing antibodies (bNAbs) targeting the envelope of human immunodeficiency virus type 1 (HIV-1) are highly efficacious when passively administered in vivo. The most active bNAbs protect against virus acquisition or dampen viral replication in humanized mice and in macaques (1) (2) (3) (4) (5) (6) . Clinical trials in viremic patients revealed that 3BNC117 or VRC01, two bNAbs that target the CD4 binding site (CD4bs) of the envelope, reduce viremia by up to 2.5 logs (7, 8) . 3BNC117 and, to a lesser extent, VRC01 can also delay viral rebound after antiretroviral treatment interruption (9, 10) . A vaccine that could generate such bNAbs is likely to be protective (11) , yet this is a challenging goal to achieve due to the rare elicitation of bNAbs during natural infection (12) and the unprecedented level of affinity maturation observed in the most active ones (13, 14) .
The RV144 vaccine trial performed in Thailand achieved a modest, but significant, 31% protection (15) . This is the only evidence of vaccine-induced protection against HIV-1 acquisition to date. Protection was not associated with the presence of broadly neutralizing antibodies in the serum of vaccinated persons but rather with anti-HIV-1 antibody-dependent cellular cytotoxicity (ADCC) activity in the absence of potentially competing anti-HIV-1 IgA antibodies (16) (17) (18) (19) . This raised the interesting possibility that non-broadly neutralizing but potent ADCC-mediating antibodies may have protective potential.
Nonneutralizing monoclonal antibodies (nnAbs) bind to numerous regions of the gp120/gp41 complex (20) (21) (22) . Targeted epitopes include a gp41 immunodominant domain (gp41ID) that corresponds to a buried loop under the gp120 trimer (23) and different conformational CD4-induced (CD4i) epitopes revealed after Env binding to CD4 (21, 22, 24) . Prototypic examples of CD4i antibodies are A32, belonging to the so-called cluster A antibodies and targeting the C1/C2 region, and 17b, targeting the coreceptor binding site (CoRBS) (25, 26) . Other nnAbs target the CD4bs or the V3 loop of gp120, without preventing virus binding or entry of most HIV-1 strains (20, (27) (28) (29) . Of note, nnAbs and bNAbs display differential binding to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits (30) . Moreover, the nnAbs tested so far do not protect against simian-human immunodeficiency virus (SHIV) acquisition in primate models, although they may marginally reduce viral loads or limit the number of founder viruses in a fraction of treated animals (23, (31) (32) (33) (34) (35) (36) (37) (38) (39) .
Several lines of evidence suggest that ADCC plays a protective role in the host response to HIV-1 infection. For instance, viral escape has been reported for ADCCtargeted epitopes, suggesting the existence of ADCC-related immune pressure on the virus (40) . Some but not all studies have correlated ADCC responses with lower viremia (41) (42) (43) , and HIV controllers display elevated ADCC activity (44, 45) . Regarding the virus itself, the accessory proteins Vpu and Nef decrease ADCC mediated by some monoclonal or polyclonal antibodies, likely by limiting the amount of Env at the surface of infected cells (24, (46) (47) (48) (49) (50) (51) . Mutation of the internalization motif in the gp41 cytoplasmic tail also increases Env surface exposure and susceptibility to ADCC (46) . The kinetics of HIV-1 suppression in infected individuals by passively administered 3BNC117 suggest that the effects of the antibody are not limited to the neutralization of viral particles but also include an acceleration of the clearance of infected cells (52) . Consistently, optimal therapeutic efficacy requires the Fc region of bNAbs (53) (54) (55) .
It has been proposed that potent ADCC-mediating antibodies mainly target regions of Env that are recognized by nonneutralizing antibodies (gp120 CD4i or gp41ID epitopes) (21, 26, 50, (56) (57) (58) . The ADCC activities mediated by nnAbs differ based on the epitope that they recognize (56, 57, 59) . Moreover, the addition of CD4 mimetics to infected cells modifies the conformation of Env at the surface, allowing the exposure of CD4i epitopes and sensitizing the cells to nonneutralizing monoclonal or polyclonal antibodies (60) (61) (62) . We and other demonstrated that a subset of bNAbs targeting the CD4bs, the V3 and V1V2 loops, and the membrane-proximal external region of gp41 (MPER) also exert a high level of ADCC in culture (51, 59, 63, 64) . This indicates that Env epitopes can be targeted by antibodies with both neutralizing and ADCC functions. We also showed that the landscape of Env epitope exposure at the surface of infected cells and the subsequent sensitivity to ADCC vary considerably between viral strains (63) . It is noteworthy that most of the studies regarding the ADCC activity of nnAbs in animal models or in cell culture systems have been performed by using a relatively limited number of different HIV-1 strains (24, 39, 49-51, 59, 60, 65-70) . Moreover, the frequent use of gp120-coated cells (26, 57, 68, 71, 72) as targets in ADCC assays is a convenient tool, but it does not fully recapitulate the levels or conformation of Env at the surface of infected cells. Indeed, levels of Env at the surface of cells infected with a wild-type virus are relatively low. Moreover, the presence of CD4 may promote the transition of recombinant Env toward an open state, which is not usually observed with HIV-1-infected cells.
Here, we analyzed the ability of anti-HIV-1 nnAbs to perform ADCC in cell culture. We selected a panel of nnAbs isolated from elite neutralizers and displaying highaffinity binding to YU-2 gp140 trimers (20, (27) (28) (29) . We performed a side-by-side comparison of the abilities of these nnAbs and of several of the most potent bNAbs to bind and kill infected cells through NK cell engagement. Almost all antibodies were able to trigger ADCC of cells infected by laboratory-adapted strains. However, the nnAbs were generally poorly active against primary HIV-1 reactivated from the reservoir or against transmitted-founder (T/F) viruses.
RESULTS
Presentation of nonneutralizing and broadly neutralizing antibodies used in this study. We and other previously isolated a large panel of anti-HIV-1 Env monoclonal antibodies from elite neutralizers by the capture of a single memory B cell using a YU-2 gp140 bait (20, (27) (28) (29) . Some of the antibodies displayed a broad neutralization profile (such as 3BNC117 or 10-1074), whereas others were ineffective or poorly active in neutralization assays (20, (27) (28) (29) . Within this second category, we selected a panel of 9 nnAbs that bind with high affinity to canonical epitopes of the gp120/gp41 complex. These epitopes include the linear immunodominant domain on gp41 (gp41ID) (4-20 and 5-25) , the CD4bs (1-863 and 2-1262), the CD4i epitopes in the CoRBS (4-8 and 4-42) , and the variable loop 3 crown (V3c) (2-59, 10-188, and 11-340) ( Table 1 ). In some of the experiments, we used the well-characterized A32 antibody, which binds another CD4i epitope localized in C1/C2 regions (22) , as a control. All antibodies were cloned into the same IgG1 backbone. As expected, the gp41ID-specific antibodies did not neutralize the NL4.3 and NLAD8 strains or the CH058 T/F strain ( Table 1 ). The other antibodies showed neutralization of some tier 1 and, more rarely, tier 2 viruses (Table 1) (20, (27) (28) (29) . For comparison purposes, we also selected 5 potent bNAbs with previously (63, 75) . We first asked whether the selected antibodies bound to T cells (CEM-NKR cell line) infected with the NLAD8 or NL4.3 reference strain. All tested antibodies bound to the fraction of cells productively infected (Gag high) with NLAD8 ( Fig. 1A and B) . Some of the nnAbs also bound to the fraction of Gag-low or Gag-negative (Gag Ϫ ) cells present in the culture. For instance, the anti-gp41ID antibodies showed a "diagonal" population on Gag-low cells, while anti-CD4i antibodies equally bound to Gag-positive (Gag ϩ ) and Gag Ϫ cells. In contrast, the bNAbs efficiently bound to Gag ϩ cells without staining the bystander cell population (Fig. 1A  and B) . A similar profile of binding was observed with NL4.3-infected cells, except for the three V3 loop-targeting nnAbs, which did not recognize this X4-tropic envelope (Fig. 1B) .
To further describe the binding of some antibodies to cells that do not express high levels of Gag, we cocultivated infected cells with target cells for 2 h and stained the cells with anti-Gag and anti-Env antibodies (Fig. 2 ). Low Gag staining was detected in a fraction of target cells, representing viral particles being transferred from infected cells to uninfected cells (76) . The CD4i and gp41ID nnAbs bound to these Gag-low or Gag-negative target cells (Fig. 2) . These results confirmed that some nnAbs bind to bystander uninfected cells that have captured HIV virions or that may be covered with shed gp120, likely because binding to CD4 induced conformational changes exposing the cryptic epitopes (61) .
We then examined the ability of nnAbs to trigger ADCC against HIV-1-infected cells. CEM-NKR cells infected with NLAD8 or NL4.3 were preincubated with the different antibodies before coculture with primary NK cells for 4 h. We evaluated the disappearance of Gag ϩ target cells as a readout of ADCC activity (63) . To facilitate comparisons, all antibodies were tested at high concentrations (15 g/ml) (59, 63) . A typical experiment showed that isotype control antibody mGO53 was inactive, whereas 5-25 and PGT128 induced the disappearance of about half of the NLAD8-infected cells (Fig. 3A) . All nnAbs (except 4-8 and 10-188) and the 5 bNAbs induced ADCC against NLAD8-infected cells (Fig. 3B ). NL4.3-infected cells were also sensitive to ADCC (Fig. 3B ). The levels of ADCC were variable among the antibodies tested, ranging from 0% to 60%, and were positively correlated with the extent of binding to infected cells (Fig. 3C) . Altogether, these data show that the majority of nnAbs tested bound to cells infected with the two laboratory-adapted HIV-1 strains and induced their killing through ADCC, displaying efficacies similar to those of bNAbs.
Activity of nnAbs against reactivated HIV-1-infected cells. Primary HIV-1 isolates may be less sensitive to ADCC than laboratory-adapted strains (59, 63) . To explore the sensitivity of primary HIV-1 to nnAbs, we first measured the exposure of Env epitopes at the surface of activated CD4 T cells isolated from patients' blood. We selected infected individuals under suppressive antiretroviral treatment (ART) (viral loads of Ͻ40 copies/ml) ( Table 2 ). We used a viral outgrowth assay in which phytohemagglutinin (PHA) treatment activates resting CD4 ϩ T cells and induces HIV-1 spread from latently infected cells (63) . HIV-1 Gag ϩ cells began to be detected at days 7 to 12 postreactivation in 8 individuals (not shown), and their numbers increased over time, indicating that viruses were infectious. Cell surface Env expression was assessed with the panel of nnAbs and bNAbs (Fig. 4) . Representative stainings of cells from two donors (donors KB47 and KB51) with 5 antibodies are presented in Fig. 4A , whereas a summary of all stainings, including both the percentage of infected cells positive for Env staining and the median fluorescence intensity (MFI) of Env staining, is displayed in Fig. 4B . In the representative examples, the nnAbs (5-25, 4-42, and 1-863) bound to Gag ϩ cells, but the MFI of binding was low. As observed with the laboratory-adapted strains, the CD4i nnAbs also bound to a subset of cells expressing undetectable or low levels of Gag, likely corresponding to bystander cells that may have captured viral material and/or to cells at an early stage of the viral life cycle. The PGT128 bNAb bound with high intensity to Gag ϩ cells and not to Gag Ϫ cells (Fig. 4A) . A comprehensive analysis of the binding of the 8 nnAbs and 5 bNAbs on cells from the 8 patients confirmed these results (Fig.  4B) . Some of the nnAbs bound to cells infected by the reactivated virus, but the intensity of binding remained low. The nnAbs also bound with low intensity to bystander cells. In contrast, the bNAbs displayed broader coverage and a higher intensity of binding to reactivated Gag ϩ cells, with minimal attachment to Gag Ϫ cells (Fig. 4) .
We further documented the binding of anti-Env antibodies to reactivated lymphocytes from patients by performing costaining with an anti-CD4 antibody. We reasoned that cells that have downregulated CD4 are likely to be productively infected and in an advanced stage of the viral life cycle, since Vpu, Nef, and Env are each able to interfere with CD4 cell surface expression (77, 78) . The Gag ϩ cells were clearly composed of two populations of cells, expressing CD4 or not at the cell surface (Fig. 5) . As expected, the Gag MFI was higher in CD4 Ϫ cells, which were preferentially and strongly bound by bNAbs. The situation was different with the nnAbs, which preferentially bound to CD4 ϩ cells expressing low levels of Gag (Fig. 5) . The MFI of nnAb binding to CD4 ϩ cells was low, confirming our results obtained with the whole cell population (Fig. 4B) .
We then used our panel of antibodies to test the sensitivity of reactivated cells to ADCC. In a representative example with cells from donor KB51, the 5-25 nnAb was ineffective, whereas PGT128 depleted half of the infected cells (Fig. 6A) . Each antibody from the panel was then tested against reactivated cells from 4 to 6 donors (Fig. 6B) . None of the nnAbs tested displayed detectable ADCC activity against these primary isolates, except for 5-25, which was moderately active against cells from some donors. In contrast, bNAbs were generally ADCC potent on cells from the majority of donors tested. Collectively, the bNAbs display significantly higher levels of ADCC than do the nnAbs (Fig. 6C) . Altogether, these results indicate that nnAbs may bind to some cells expressing reactivated viral strains, but the intensity of binding is generally not sufficient to allow ADCC.
Binding of nnAbs to cells infected with T/F HIV-1 strains. We extended our analysis of the recognition of infected cells by nnAbs to other primary HIV-1 strains that might be relevant during transmission between individuals. CEM-NKR cells were infected with 8 T/F HIV-1 strains (79) and costained with anti-Gag and anti-Env antibodies.
A representative example with CH058 shows that two nnAbs (5-25 and 4-42) bound poorly to infected cells, whereas the NIH45-46 and PGT128 bNAbs bound strongly (Fig.  7A) . When the whole panel of nnAbs and bNAbs was tested against the 8 T/F viruses, we observed a strong dichotomy between the two categories of antibodies. The percentage of infected cells stained with nnAbs remained consistently low (Fig. 7B) , and among positive cells, the MFI of staining was also low for nnAbs (not shown). These results confirmed that the binding of bNAbs to T/F HIV-1 strains is variable (63) . However, each of the 5 bNAbs bound to 3 to 5 of the 8 T/F strains, and a strong intensity of staining was often observed (Fig. 7A and data not shown) . Conversely, each of the 8 T/F viruses was targeted by 1 to 5 of the 5 bNAbs (Fig. 7B and data not shown) . Therefore, the breadth of recognition of cells infected with primary HIV isolates, including reactivated virus from the reservoir and T/F strains, is particularly limited for nnAbs.
A small CD4-mimetic sulfopeptide conjugate modulates the activity of nnAbs. Small CD4 mimetics modify the conformation of Env at the cell surface and sensitize HIV-1-infected cells to ADDC mediated by nonneutralizing polyclonal antibodies present in sera and other fluids from HIV-1-infected individuals (60) . We thus examined the effect of mCD4.2-PS1 on the binding and ADCC activity of our panel of nnAbs and bNAbs. mCD4.2-PS1 is a recently described CD4-mimetic sulfopeptide conjugate that binds to HIV-1 Env and inhibits cell-free and cell-associated HIV-1 with particularly low 50% inhibitory concentrations (IC 50 s), in the picomolar-to-nanomolar range (80) . mCD4.2-PS1 binds gp120 through its mCD4 moiety and induces the structural modifications necessary to expose the coreceptor binding domain, which, as a result, becomes available to be blocked by the PS1 moiety (81). We first examined the effect of mCD4.2-PS1 on Env epitope exposure. CEM cells infected with NLAD8 or CH058 and primary CD4 ϩ T cells infected with the reactivated virus from patient KB18 (KB18v) were incubated with mCD4.2-PS1 (10 nM) for 10 min before staining with the panel of nnAbs and bNAbs. A representative example with CH058-infected cells shows that the binding of the 5-25 nnAb was strongly enhanced by mCD4.2-PS1, whereas the staining of the 3BNC117 bNAb was decreased, likely because both molecules compete for the CD4bs on gp120 (Fig. 8A ). An analysis of the panel of antibodies confirmed that for cells infected with the CH058 and KB18v viruses, the staining of some nnAbs (mostly those targeting the V3 loop and the gp41ID epitopes) was increased (Fig. 8B) . As expected, the nnAbs targeting the CD4bs were inhibited in their binding, whereas the CD4i epitope was not significantly enhanced. The sensitivity of bNAbs to mCD4.2-PS1 varied depending on the viral strain, but none of the 5 bNAbs tested displayed enhanced binding after treatment with mCD4.2-PS1 (Fig. 8B) .
We then assessed the effect of mCD4.2-PS1 on the ADCC activity of the nnAbs and bNAbs. T cells infected with either CH058 or KB18v were incubated or not with mCD4.2-PS1 before being used as targets in ADCC assays ( Fig. 8C and D) . The small CD4 mimetic enhanced the ADCC potency of some nnAbs, reflecting their increased binding to infected cells. The ADCC efficacy of the bNAbs was decreased with CH058 and not affected with KB18v, mirroring the effect of mCD4.2-PS1 on bNAb binding.
We then examined how the prototypic CD4i anti-cluster A A32 antibody (25) behaves in our assays, since A32-like antibodies constitute the majority of the ADCC activity observed in HIV-1-infected or RV144-vaccinated individuals (21, 26, 50, 68, 71, 82) . Using lymphocytes infected with KB18v, we observed that the profile of A32 binding was comparable to that of CD4i CoRBS antibodies 4-8 and 4-42, with preferential staining for Gag-low or -negative cells (Fig. 9) . The intensity of staining was not enhanced by mCD4.2-PS1 (Fig. 9) . Accordingly, none of the three CD4i nnAbs (targeting either cluster A or the CoRBS) induced efficient ADCC against KB18v-infected cells in the absence or presence of mCD4.2-PS1 (Fig. 9) .
Altogether, these results indicate that a small CD4 mimetic enhances the binding and ADCC activity of some but not all nnAbs. However, the combination of mCD4.2-PS1 and nnAbs does not seem to be superior to bNAbs used without the mimetic.
DISCUSSION
A correlate analysis of the RV144 vaccine trial suggested a protective role of nnAbs displaying ADCC activity in the prevention of HIV-1 acquisition (17-19) . However, subsequent studies in primates failed to demonstrate a protective role of passively administered nonneutralizing single or pooled monoclonal antibodies or polyclonal antibodies (23, 33, 34, 37, 38) . The transfer of polyclonal, ADCC-inducing antibodies isolated from an elite controller that exhibited nonneutralizing control of infection also did not protect against SHIV challenge (36) . In contrast, the passive transfer of the most active bNAbs mediates sterilizing protection in primate models (1) (2) (3) (4) (5) (6) . Thus, the role of nonneutralizing antibodies with ADCC activity in protection from infection or slowing disease progression remains debatable and partly understood. Here, we have addressed this question by characterizing the activity of a panel of nine nonneutralizing monoclonal antibodies in cell culture systems. We analyzed the ability of the nnAbs to bind to HIV-1-infected cells and to mediate ADCC through NK lysis. The nnAbs were selected to cover some of the known nonneutralizing epitopes present on the gp120/ gp41 complex and to bind with high affinity to the HIV-1 YU-2 gp140 trimer (20, (27) (28) (29) . Their activity was compared to those of five of the most active bNAbs, including those that we and others recently demonstrated to be potent in eliminating HIV-1-infected cells through ADCC (51, 59, 63) .
We analyzed the binding activity of the nonneutralizing and neutralizing antibodies in lymphocytes infected with up to 18 different HIV-1 strains, including 2 HIV-1 reference strains (NL4.3 and NLAD8), 8 isolates reactivated from patients under suppressive treatment, and 8 T/F viruses. Strikingly, the nnAbs efficiently bound to cells infected with the reference strains but were generally modestly able to bind to T cells infected with the primary isolates. Our results reveal an unexpected lack of breadth of nnAbs, a phenomenon that cannot be observed in classical neutralization assays with cell-free viral particles, since the antibodies are, by definition, nonneutralizing. Moreover, we report that nnAbs often bind preferentially to bystander cells present in the culture. Bystanders are defined as cells displaying low levels of Gag and an absence of CD4 downregulation and likely correspond to cells that have recently captured viral particles or are covered by shed gp120 from neighboring productively infected cells. This preferential binding to bystander cells was previously reported for other monoclonal or polyclonal nonneutralizing antibodies (61, 83) . This is likely the consequence of intrinsic properties of nnAbs, which are not able to bind to the fully closed state of the viral envelope (84) . The binding of Env to CD4 molecules present on noninfected cells will induce conformational changes, revealing the hidden epitopes targeted by some of the nnAbs. For instance, the binding of gp41ID nnAbs to both Gag ϩ and Gag Ϫ cells is probably due to the recognition of a nonfunctional trimeric Env spike, more specifically gp41 stumps (83) . In comparison with the nnAbs, the recognition profile of bNAbs is wide, and they preferentially target productively infected cells rather than neighboring cells.
We and other previously reported that a prerequisite for the ADCC activity of a given bNAb is its ability to stably bind to infected cells (46, 56, 59, 63) . The affinity of binding to target cells, measured as the MFI of staining analyzed by flow cytometry, also correlates with the efficacy of ADCC (63) . In agreement with the poor binding of the nnAbs to most of the viral isolates tested, we show that these antibodies are inefficient at eliminating cells producing primary virus from the viral reservoir or cells infected with T/F strains. This is again in contrast to the ability of bNAbs to eliminate infected cells, as demonstrated here and in recent studies in cell culture and in vivo (51, 52, 59, 63) .
Small CD4 mimetics with the capacity to trigger the CD4-bound conformation of Env enhance the recognition of infected cells by serum or other antibody-containing fluids from HIV-infected individuals (60) (61) (62) . Here, we have tested the impact of mCD4.2-PS1, a CD4-mimetic sulfopeptide conjugate, on the efficacy of our panel of nnAbs. In agreement with data from previous reports, we observed an enhancement of binding and ADCC activity by some of the nnAbs, indicating that the compound induced conformational changes in Env at the surface of infected cells. However, the increased efficacy was somewhat modest and did not reach the antiviral effect observed with the bNAbs. Interestingly, mCD4.2-PS1 facilitated the binding of nnAbs targeting the gp41ID or the V3 epitopes but did not induce the exposition of the CD4i epitope (using either anti-CoRBS or anti-cluster A antibodies), at least with the 2 viral strains tested. This can be due to the structure of mCD4.2-PS1, including a sulfopeptide conjugate targeting the CD4i epitope, thus competing with the binding of CD4i antibodies (81) . However, we cannot exclude that this compound may stabilize Env in a conformation different from that observed for other CD4 mimetics. It has also been reported that small CD4 mimetics require the addition of antibodies targeting the coreceptor binding site to facilitate recognition by CD4i nnAbs (62) .
It has been proposed that CD4i antibodies or other nnAbs that recognize Env epitopes exposed after virus binding to uninfected cells may mediate ADCC at an early step of the viral replication cycle (21, 57, 85, 86) . Such antibodies might thus mediate the elimination of infected cells more efficiently than those targeting epitopes exposed at later stages of infection. However, our results show that the intensity of nnAb staining of bystander cells does not surpass that of bNAbs on productively infected cells. Moreover, we did not detect a significant elimination of bystander cells by nnAbs when we used the number of NK cells as a reference in our ADCC assay (not shown).
We cannot rule out that the 9 nnAbs tested here are not the most potent ones. However, we show that the prototypic anti-cluster A CD4i antibody A32 (22) does not display strong ADCC against cells infected by a virus isolated from one patient. Numerous other nnAbs have been isolated and tested in ADCC assays (57, 65, 67, 68, 71, 87) . It will be worth determining whether they display a broader recognition of HIV-1-infected cells, since most previous studies were based on a relatively low number of primary cross-clade viral isolates or used gp120-coated cells as ADCC targets (24, 39, 50, 60, (65) (66) (67) (68) (69) (70) . Future experiments in animal models and in human cell cultures will also help evaluate the efficacy of nnAbs, used alone or in combination with other nnAbs, bNAbs, and CD4 mimetics, in the elimination of infected cells.
In summary, our data suggest that the breadth of recognition of HIV-1-infected cells by nnAbs is narrow and that bNAbs display a broader and higher ADCC capacity than do nnAbs.
MATERIALS AND METHODS
Cells and viruses. The CEM-NKR-CCR5 cell line (referred to as CEM-NKR) was obtained from the NIH AIDS Reagent Program. NK cells were purified from human peripheral blood (obtained anonymously from the Etablissement Français du Sang [EFS]) by density gradient centrifugation followed by immunomagnetic selection (Miltenyi). The purity of NK cells was 90 to 98%. NK cells were maintained in complete medium, and interleukin-2 (IL-2) (50 IU/ml) was added the day before use. Virus stocks were prepared by the transfection of 293T cells (obtained from the ATCC) along with vesicular stomatitis virus G (VSV-G) to normalize infectivity (88) . Cells were infected with NL4.3, NLAD8, and transmitted-founder HIV-1 strains (CH040, CH058, CH077, CH106, RHPA, THRO, REJO, and WITO; obtained from the NIH AIDS Reagent Program) as described previously (89) . Viral inocula (25 to 100 ng of p24/10 6 cells) were adjusted to achieve similar levels of Gag ϩ cells (around 40 to 50%) at 48 h postinfection.
Antibodies and the CD4 mimetic. Anti-Env nnAbs and bNAbs, as well as the isotypic control mGO53, were produced as recombinant monoclonal antibodies carrying the same human IgG1 Fc region by the cotransfection of 293T or 293F cells (obtained from the ATCC) as previously described (27) . Antibodies were purified by batch/gravity-flow affinity chromatography using protein G-Sepharose 4 fast-flow beads (GE Healthcare). The CD4 mimetic (mCD4.2-PS1) was prepared by chemical synthesis and characterized as previously described (80) .
ADCC assay. The ADCC assay was performed as previously described (63) . HIV-1-infected target CEM-NKR or primary CD4 T cells (obtained anonymously from the EFS) were stained by using the Far-Red cell tracker (Life Technologies). Totals of 2 ϫ 10 4 to 5 ϫ 10 4 targets were plated into U-bottom 96-well plates and incubated with antibodies (15 g/ml) for 5 min at room temperature. Heterologous NK cells were added to each well (at a ratio of 1 CEM-NKR cell to 10 NK cells or 1 primary CD4 T cell to 1 NK cell). Plates were spun for 1 min at 300 ϫ g to promote cell contacts and incubated at 37°C for 6 h (for primary CD4 T cells) or 4 h (for CEM-NKR cells). Cells were then stained for intracellular Gag as previously described (88) . Data were acquired on a FACS Canto II instrument (BD Biosciences) or an Attune Nxt instrument (Life Technologies) and analyzed by using FlowJo software. The frequencies of Gag ϩ cells among Far-Red ϩ cells were determined. ADCC was calculated by using the following formula: 100 ϫ (% of Gag ϩ target cells plus NK cells without antibody Ϫ % of Gag ϩ target cells plus effector cells with antibody)/(% of Gag ϩ target cells plus NK cells without antibody). Negative values were set to zero. In some experiments, we used the number of NK cells in the culture as a reference to specifically measure the disappearance of p24 Ϫ cells.
Staining of HIV-1-infected cells with nnAbs and bNAbs. Cells (0.5 ϫ 10 4 to 2 ϫ 10 4 cells per well) were incubated for 30 min at 37°C with anti-Env bNAbs or with an isotypic human IgG1 control (mGO53) at 15 g/ml diluted in culture medium. Cells were then washed and incubated for 30 min at 4°C with anti-human IgG1(HϩL) Alexa Fluor 647 (1:400 dilution; Life Technologies). Cells were then fixed with 4% paraformaldehyde (PFA) and processed for intracellular Gag staining.
Neutralization assay. Neutralization of cell-free HIV-1 was measured by using the Tzm-BL cell line (obtained from the NIH AIDS Reagent Program) as previously described (90) . Dose-response inhibition curves were drawn by fitting the data to sigmoid dose-response curves (variable slope) using GraphPad Prism software. The percentage of inhibition was defined as (% signal in nontreated target cells Ϫ % signal in bNAb-treated cells)/(% signal in nontreated target cells) ϫ 100. The IC 50 was calculated with GraphPad Prism.
Reactivation of HIV-1 from highly active antiretroviral therapy (HAART)-treated patients. For each patient, 50 ml of blood was harvested in the presence of EDTA. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient purification, and CD4 T cells were purified as described above. For the viral outgrowth assay, CD4 T cells were stimulated with PHA-M (2 mg/ml; Sigma-Aldrich) or anti-CD2,3 and -CD28 beads (1 bead for 2 cells; Miltenyi Biotech) with 100 IU/ml of IL-2 (R&D) at 1 ϫ 10 6 cells/ml. Every 2 to 3 days, 1 ml of the supernatant was harvested and replaced with fresh medium. At the indicated time points, cells were evaluated for Gag expression and antibody binding by flow cytometry. Cells were used for ADCC experiments when the fraction of Gag ϩ cells was above 5%. The KB18v HIV-1 strain isolated from patient KB18 was amplified once in primary CD4 ϩ T cells.
Data processing and statistical analysis. Calculations were performed and figures were drawn by using Excel 2011 or GraphPad Prism 5.0. Statistical analysis was performed by using GraphPad Prism, with Wilcoxon matched-paired t tests or Mann-Whitney unpaired t tests. Spearman correlation coefficients (r) were calculated by using GraphPad Prism.
Ethics statement. All patients were from the Hôpital Kremlin Bicêtre (Kremlin Bicêtre, France) under successful HAART (Table 2) . Each participant provided written consent to participate in the study, which was approved by the regional investigational review board (IRB) (Comité de Protection des Personnes Ile-de-France VII, Paris, France) and performed according to European guidelines and the Declaration of Helsinki. All samples were anonymized. All subjects were adults.
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